The development of bispecific agents - molecules designed to simultaneously bind two different cell surface receptors – is an avenue promising increased efficacy and specificity in targeted therapies.1–8 Most bispecific agents act in trans, in order to, for example, recruit immune cells to cancer cells. Here, CD177 is linked to cancer.